Compare Organon & Co. Common Stock (OGN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Xylem, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Xylem, Inc. trades at $103.51 (market cap $23.99B). The key difference: Xylem, Inc. is far larger — about 6.6× Organon & Co. Common Stock's market cap, and Xylem, Inc. pays the higher dividend (1.67%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| OGN | XYL | |
|---|---|---|
Market Cap | $3.61B | $23.99B |
Volume | 1,808,049 | 2,429,384 |
Sector | Health | Industrials |
52-Week High | $13.81 | $152.95 |
52-Week Low | $5.70 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $11.03B | $25.77B |
Dividend Yield | 0.58% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Xylem (XYL) trades at $102.54, down slightly by 0.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue has grown from $5.5B in 2022 to $9.04B in 2025, with net income margins improving to 10.59%. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, alongside a new CFO appointment.
The outlook is supported by steady revenue growth, margin expansion, and strategic acquisitions in water technology, though near-term sentiment is cautious due to technical weakness and China-related headwinds. Risks include execution of acquisitions and debt increase, but analyst consensus price target of $146.63 implies significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
